Since early May, and as of 11 October 2022, 20 455 confirmed cases of monkeypox (MPX) have been reported from 29 European Union/European Economic Area (EU/EEA) countries, including four deaths. As of 30 September, MPX confirmed cases reported from EU/EEA countries represented almost one third (29.7%) of the cases reported to the World Health Organization (WHO) globally (68 267 cases).
ECDC assessed the risk to the EU/EEA of the presence and the possible transmission of prions, which have been linked to Creutzfeldt-Jakob disease, by blood and plasma-derived medicinal products (PDMPs) manufactured from donations obtained in the UK.
Since early May 2022 and as of 7 July, cases of monkeypox (MPX) have been reported in non-endemic countries. Twenty-six European Union/European Economic Area (EU/EEA) countries have reported 4 908 cases, representing 65% of all cases reported worldwide in 2022.
Cases of monkeypox (MPX) acquired in the EU have recently been reported in nine EU Member States (Austria, Belgium, France, Germany, Italy, Portugal, Spain, Sweden, and the Netherlands).
On 17 February 2022, the United Kingdom (UK) reported a cluster of cases with monophasic Salmonella Typhimurium sequence type 34 infection. As of 18 May 2022, 324 cases had been reported in 12 EU/EEA countries and the UK, including two distinct strains.
This interactive video lecture is intended to help you understand the behavioural aspects behind multidrug-resistant microorganisms (MDROs) prevention and control interventions.
An increase in severe acute hepatitis cases of unknown aetiology among previously healthy children was first reported by the United Kingdom (UK) on 5 April 2022.
On 17 February 2022, the United Kingdom (UK) reported a cluster of cases with monophasic Salmonella Typhimurium sequence type 34 infection. By 8 April 2022, 150 cases had been reported in nine EU/EEA countries and the UK. Most cases are below 10 years of age and many children have been hospitalised.
This document assesses the risk of further spread of S. sonnei amongst MSM and in the broader population in EU/EEA countries, resulting from the current increase in extensively-drug resistant S. sonnei infections.